Edison, NJ, United States of America

Seujo Lee

This inventor holds 1 USPTO granted patent. Top assignee: Celgene Corporation. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Seujo Lee

Introduction

Seujo Lee is a notable inventor based in Edison, NJ, who has made significant contributions to the field of chemistry. His work primarily focuses on the preparation of chiral compounds, which are essential in various pharmaceutical applications. With a single patent to his name, Lee's innovative approach has garnered attention in the scientific community.

Latest Patents

Seujo Lee holds a patent for a process titled "Process for the preparation of chiral 1-aryl-2-aminopropanes." This patent describes a method for producing one chiral form of a 1-aryl-2-aminopropane preferentially over its enantiomer. The process involves allowing a 1-arylpropan-2-one to react with a 1-amino-1-phenylethane of predominantly one chiral form. The resultant compound is then reduced to yield a mixture of 1-aryl-2-aminopropanes, which can be further processed to isolate the desired chiral form.

Career Highlights

Lee is currently employed at Celgene Corporation, where he continues to apply his expertise in the field of chiral chemistry. His work at Celgene has allowed him to collaborate with other talented professionals and contribute to the development of innovative pharmaceutical solutions.

Collaborations

One of his notable coworkers is George W Matcham, with whom he has likely shared insights and expertise in their respective fields. Their collaboration may have further enhanced the research and development efforts at Celgene Corporation.

Conclusion

In summary, Seujo Lee's contributions to the field of chiral chemistry through his patent and work at Celgene Corporation highlight his role as an innovative inventor. His research continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…